Jeffrey Lynn Probstfield

Q: What Schools Are Affiliated With Jeffrey Lynn Probstfield

Jeffrey Lynn Probstfield is affiliated with the following schools: McMaster University, Baylor College of Medicine, University of Washington

Jeffrey Lynn Probstfield's AcademicInfluence.com Rankings

Philosophy

#7754

World Rank

#11005

Historical Rank

Logic

#4790

World Rank

#6119

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Jeffrey Lynn Probstfield's Degrees

Doctorate Medicine University of Washington

Why Is Jeffrey Lynn Probstfield Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jeffrey Lynn Probstfield's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (2002) (5253)
Effects of intensive glucose lowering in type 2 diabetes. (2008) (4946)
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. (1989) (3118)
Effects of intensive blood-pressure control in type 2 diabetes mellitus. (2010) (3094)
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. (2011) (2581)
Effects of combination lipid therapy in type 2 diabetes mellitus. (2010) (2425)
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. (1998) (2280)
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2009) (2033)
Spironolactone for heart failure with preserved ejection fraction. (2014) (1835)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. (2015) (1755)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (2017) (1499)
Basal insulin and cardiovascular and other outcomes in dysglycemia. (2012) (1458)
Homocysteine lowering with folic acid and B vitamins in vascular disease. (2006) (1166)
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. (2005) (1119)
Long-term effects of intensive glucose lowering on cardiovascular outcomes. (2011) (950)
High-Density Lipoprotein Cholesterol and Cardiovascular Disease (2005) (946)
Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. (1999) (924)
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. (1991) (911)
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. (1994) (892)
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. (2012) (814)
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial (2015) (709)
Erectile dysfunction and subsequent cardiovascular disease. (2005) (635)
Effect of ramipril on the incidence of diabetes. (2006) (569)
Urinary sodium and potassium excretion and risk of cardiovascular events. (2011) (538)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. (2007) (530)
Use of ramipril in preventing stroke: double blind randomised trial (2002) (427)
Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial (2010) (409)
Recruitment for controlled clinical trials: literature summary and annotated bibliography. (1997) (401)
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2005) (352)
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low–Left Ventricular Ejection Fraction Trials (2004) (349)
Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). (2000) (321)
Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. (1996) (315)
High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. (1986) (311)
Association of Angiotensin-Converting Enzyme With Low-Density Lipoprotein in Aortic Valvular Lesions and in Human Plasma (2002) (299)
Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril (2005) (270)
Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. (2000) (263)
Features of the Metabolic Syndrome and Diabetes Mellitus as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis (2006) (262)
Recruitment experience in clinical trials: literature summary and annotated bibliography. (1987) (257)
Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. (2019) (249)
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. (2005) (244)
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. (2007) (234)
Blood-pressure reduction and cardiovascular risk in HOPE study (2001) (221)
Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study. (2000) (218)
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. (2013) (217)
Surrogate endpoints in clinical trials: cardiovascular diseases. (1989) (216)
Characterization of health‐related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM (2007) (213)
Statin Therapy and Outcome After Ischemic Stroke: Systematic Review and Meta-Analysis of Observational Studies and Randomized Trials (2013) (203)
Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure (2005) (200)
Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. (2005) (195)
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals (2011) (189)
Predictive value of the exercise tolerance test for mortality in North American men: the Lipid Research Clinics Mortality Follow-up Study. (1986) (159)
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide (2018) (156)
Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONT (2010) (156)
Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease: Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2014) (150)
Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes (2016) (148)
Relationship Between Healthy Diet and Risk of Cardiovascular Disease Among Patients on Drug Therapies for Secondary Prevention: A Prospective Cohort Study of 31 546 High-Risk Individuals From 40 Countries (2012) (147)
Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. (1996) (144)
Decrease in plasma high-density lipoprotein cholesterol levels at puberty in boys with delayed adolescence. Correlation with plasma testosterone levels. (1987) (141)
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. (2017) (133)
Effect of Telmisartan on Renal Outcomes (2009) (127)
Cognitive impairment and risk of cardiovascular events and mortality. (2012) (125)
Aortic valve calcium independently predicts coronary and cardiovascular events in a primary prevention population. (2012) (123)
Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes (2017) (108)
Coronary heart disease morbidity and mortality in hypercholesterolemic men predicted from an exercise test: the Lipid Research Clinics Coronary Primary Prevention Trial. (1989) (108)
Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk (2016) (107)
Hemodynamic Effects of the Angiotensin-Converting Enzyme Inhibitor, Ramipril, in Patients with Mild to Moderate Aortic Stenosis and Preserved Left Ventricular Function (2004) (100)
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. (2015) (100)
Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). (2007) (97)
Plasma lipid and lipoprotein response of humans to beef fat, coconut oil and safflower oil. (1985) (93)
Progression of cardiovascular damage: the role of renin-angiotensin system blockade. (2010) (88)
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-IN (2007) (87)
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. (2019) (83)
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. (2009) (82)
Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies. (2011) (79)
Pantoprazole to Prevents Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-blind, Placebo-controlled Trial. (2019) (79)
Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. (1995) (79)
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial (2020) (78)
Safety profile of extended-release niacin in the AIM-HIGH trial. (2014) (77)
Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study (2011) (76)
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry (2018) (76)
The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia (2014) (76)
Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. (2016) (76)
Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2012) (72)
Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. (1998) (72)
Strategies for recruitment and retention of participants in clinical trials. (2011) (71)
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease (2019) (69)
Role of B‐Type Natriuretic Peptide and N‐Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus (2017) (67)
Relationship between coronary artery and descending thoracic aortic calcification as detected by computed tomography: the Multi-Ethnic Study of Atherosclerosis. (2009) (67)
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. (2012) (66)
NIH consensus development conference draft statement on vaginal birth after cesarean: new insights. (2010) (66)
Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. (1997) (65)
Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. (1995) (59)
Progression and regression of carotid atherosclerosis in clinical trials. (1991) (59)
Incidence and Predictors of Angioedema in Elderly Hypertensive Patients at High Risk for Cardiovascular Disease: A Report From the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2006) (58)
How cost-effective are new preventive strategies for cardiovascular disease? (2003) (58)
Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. (1992) (56)
Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2011) (52)
Healthy eating and reduced risk of cognitive decline (2015) (52)
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. (2020) (52)
Major clinical trials of hypertension: what should be done next? (2005) (50)
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease (2020) (49)
Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. (1999) (49)
Effect of long-term therapy with ramipril in high-risk women. (2002) (49)
Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT) (2005) (49)
Analysis strategies for serial multivariate ultrasonographic data that are incomplete. (1992) (49)
Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial. (2006) (47)
Methodological issues facing studies of atherosclerotic change. (1993) (46)
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial (2011) (46)
Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. (1994) (45)
Mass mailing and staff experience in a total recruitment program for a clinical trial: the SHEP experience. Systolic Hypertension in the Elderly Program. Cooperative Research Group. (1999) (44)
Mortality and Morbidity During and After the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (2012) (43)
Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (1998) (42)
Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). (1995) (41)
Venous thromboembolism in association with features of the metabolic syndrome. (2007) (40)
Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. (2007) (40)
Evaluating effects of treatment in subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers. (1990) (40)
Recruitment in NHLBI population-based studies and randomized clinical trials: data analysis and survey results. (1987) (38)
Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal DiseaseNovelty and Significance (2014) (37)
Lipid Research Clinics Coronary Primary Prevention Trial (1986) (37)
Systolic Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. (1991) (36)
Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. (2007) (36)
Racial differences in outcome and treatment effect in congestive heart failure. (2005) (35)
Interaction of age with lipoproteins as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis. (2008) (34)
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. (1989) (33)
The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial. (2020) (32)
The Mini‐Mental State Examination, Clinical Factors, and Motor Vehicle Crash Risk (2014) (32)
Long‐Term Follow‐Up of Moderately Hypercholesterolemic Hypertensive Patients Following Randomization to Pravastatin vs Usual Care: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT) (2013) (32)
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes (2015) (31)
Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Results by Sex (2013) (30)
Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme (2005) (30)
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI) (2020) (29)
Smoking, physical activity, and other predictors of endurance and heart rate response to exercise in asymptomatic hypercholesterolemic men. The Lipid Research Clinics Coronary Primary Prevention Trial. (1987) (28)
Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia. (1981) (27)
The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD. (2018) (26)
Characteristics and Long-Term Follow-Up of Participants with Peripheral Arterial Disease During ALLHAT (2014) (26)
Longer duration of statin therapy is associated with decreased carotid plaque vascularity by magnetic resonance imaging. (2016) (25)
Successful program for recovery of dropouts to a clinical trial. (1986) (25)
Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration (2018) (25)
Relationship between common carotid intima-media thickness and thoracic aortic calcification: the Multi-Ethnic Study of Atherosclerosis. (2010) (24)
Age-modification of lipoprotein, lipid, and lipoprotein ratio-associated risk for coronary artery calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA]). (2010) (23)
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022) (23)
Occupational screenings: recruitment from private industry. (1982) (23)
Treatment resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2014) (23)
Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. (1999) (23)
Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease. (2020) (22)
Conclusions and implications of the systolic hypertension in the elderly program. (1993) (21)
TSH response to TRH in euthyroid, hypercholesterolemic patients treated with graded doses of dextrothyroxine. (1981) (20)
Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes (2011) (20)
Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial (2013) (20)
Recruitment strategies in the studies of left ventricular dysfunction (SOLVD): strategies for screening and enrollment in two concurrent but separate trials. The SOLVD Investigators. (1992) (19)
Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial (2010) (18)
The combination oral and nutritional treatment of late‐onset diabetes mellitus (CONTROL DM) trial results (2004) (18)
Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. (2017) (17)
Examination of medical professions for counseling on medication adherence. (1985) (17)
Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. (1994) (17)
Statin Therapy and Outcome After Ischemic Stroke (2013) (17)
Cation Transport in Duchenne Muscular Dystrophy Erythrocytes (1972) (16)
RELATION OF TREADMILL EXERCISE TEST PERFORMANCE TO HABITUAL VIGOROUS EXERCISE AND CORONARY RISK FACTORS IN APPARENTLY HEALTHY HYPERCHOLESTEREMIC MEN (1985) (16)
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. (2014) (16)
National Institutes of Health Consensus Development Conference Statement: Vaginal Birth After Cesarean Section (2011) (16)
The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers. (2012) (16)
The lipid research clinics coronary primary prevention trial: Design, results, and implications (2005) (15)
Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT). (2009) (15)
Effects of Telmisartan on Glucose Levels in People at HighRisk for Cardiovascular Disease but Free FromDiabetes The TRANSCEND study (2011) (14)
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. (2020) (14)
Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome (2020) (13)
Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. (2017) (13)
Coronary risk factors and exercise test performance in asymptomatic hypercholesterolemic men: application of proportional hazards analysis. (1984) (13)
High-density lipoprotein response to 5-alpha-dihydrotestosterone and testosterone in Macaca fascicularis: a hormone-responsive primate model for the study of atherosclerosis. (1990) (13)
Videocassette use in diet instruction. (1983) (12)
Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. (2017) (12)
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial (2018) (11)
Part 1: Rationale and Design (1991) (11)
Task identification in pediatric practice. (1969) (11)
Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). (1992) (11)
Stages of systemic hypertension and blood pressure as correlates of computed tomography-assessed aortic valve calcium (from the Multi-Ethnic Study of Atherosclerosis). (2011) (11)
Plasma lipid effects of three common vegetable oils in reduced-fat diets of free-living adults. (1994) (11)
Blood pressure control in the anthihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) (1998) (11)
Clinical and demographic correlates of medication and visit adherence in a large randomized controlled trial (2016) (11)
Adherence and its management in clinical trials: implications for arthritis treatment trials. (1989) (10)
Performance analysis in pediatric practice: preliminary report. (1967) (10)
Cardioprotective Strategies to Improve Long‐Term Outcomes Following Coronary Artery Bypass Surgery (2006) (10)
Early head‐to‐pelvis computed tomography in out‐of‐hospital circulatory arrest without obvious etiology (2021) (9)
Neurohumoral variability in left ventricular dysfunction (1995) (9)
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis (2020) (9)
Intervention specialist: new role for dietitians' counseling skills. (1984) (9)
Community volunteers as recruitment staff in a clinical trial: the systolic hypertension in the elderly program (SHEP) experience. (1996) (9)
Alterations in human serum alkaline phosphatase and its isoenzymes by hypolipidemic agents: colestipol and clofibrate. (1983) (8)
Recent Trends in Adherence to Secondary Prevention Guidelines for Patients Undergoing Coronary Revascularization in Washington State: An Analysis of the Clinical Outcomes Assessment Program (COAP) Registry (2012) (8)
The Lipid Research Clinics Coronary Primary Prevention Trial: design, results, and implications (2011) (8)
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial (2022) (8)
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline (2020) (7)
Diagnostic Accuracy of Early Computed Tomographic Coronary Angiography to Detect Coronary Artery Disease After Out-of-Hospital Circulatory Arrest. (2020) (7)
Carotenoids and vitamin A: the effect of hypocholesterolemic agents on serum levels. (1985) (7)
Risk of Hospitalized Gastrointestinal Bleeding in Persons Randomized to Diuretic, ACE‐Inhibitor, or Calcium‐Channel Blocker in ALLHAT (2013) (6)
Re: Hawkins RG, Houston MC Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am J Hypertens. 2005 Jun;18(6):744-9. (2006) (6)
Assessment of staff interviewing and counseling skills for medication adherence in a clinical trial (1980) (5)
A successful program for returning dropouts to a clinical trial (1980) (5)
Identification of varied training needs of a clinical trial staff by objective documentation of their interviewing and counseling skills (1981) (5)
Commentary:Clinical trials methods and the practice of medicine (1984) (5)
Producing video cassette programs for diet instruction. (1981) (5)
Selecting screening criteria for clinical trials: an example from the Systolic Hypertension in the Elderly Program. (1999) (5)
Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial. (2011) (5)
The Public Health and Clinical Implications of the National Increase in Congestive Heart Failure (1987) (5)
Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort. (2018) (4)
Part 2: Screening and Recruitment (1991) (4)
Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial (2020) (4)
Detection of dyslipoproteinemia with the use of plasma total cholesterol and triglyceride as screening tests. The Lipid Research Clinics Program Prevalence Study. (1986) (4)
Development of standardized simulated patients for quality control of the clinical interview. (1983) (4)
Ramipril prevents major cardiovascular events in high-risk women: results of the HOPE trial (2002) (4)
Systolic hypertension in the elderly: controlled or uncontrolled. (1990) (3)
1333: Association of Erectile Dysfunction and Subsequent Cardiovascular Disease (2006) (3)
Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects (2021) (3)
Systolic hypertension in the elderly program (SHEP). II, Screening and recruitment (1991) (3)
Hemostatic Effects of 1 mg Daily Warfarin on Post CABG Patients (1999) (3)
II, SCREENING AND RECRUITMENT (1991) (3)
Development of standardized simulated patients for quality control of the clinical interview (1983) (3)
New Trial Data on Prevention: Potassium and CV Risk in Hope (2003) (3)
The Hemostatic Effects of Warfarin Titration in Post CABG Patients in Comparison to Placebo Treatment (2001) (3)
THE COMPARABLE UTILITY OF COMPUTED TOMOGRAPHY AND ECHOCARDIOGRAPHY IN THE DETECTION OF EARLY STAGE CALCIFIC AORTIC VALVE DISEASE: AN AGES-REYKJAVIK INVESTIGATION. (2010) (2)
Beneficial effects of ramipril on cardiovascular events in high-risk patients older than 75 years of age: Secondary outcomes from the HOPE trial (2003) (2)
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease (2021) (2)
Age modification of the association of lipoprotein, lipid, and lipoprotein ratio with carotid intima-media thickness (from the Multi-Ethnic Study of Atherosclerosis [MESA]). (2012) (2)
Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes (2022) (2)
Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. (2022) (2)
SUBGROUP ANALYSIS OF CLINICAL TRIALS. REPLY (1991) (2)
Response to Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016;39:973–981 (2016) (2)
Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT. (2017) (2)
Cholesterol and total mortality (1992) (2)
Prevention of Stroke in Older Persons With Isolated Systolic Hypertension-Reply (1991) (2)
Angiotensin-Converting Enzyme Inhibitors and Change in Aortic Valve Calcium (2005) (2)
Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial (2020) (2)
How can clinical researchers quantify the value of their proposed comparative research? (2019) (2)
The systolic hypertension in the elderly program. Implications for nursing practice and research. (1989) (2)
Summary of clinical and laboratory data of study subjects with and without DCE-MRI plaque measurements in the AIM-HIGH clinical trial (2016) (2)
Angioedema in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) (2005) (2)
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. (2022) (2)
Long term adherence in patients who fail the initial prerandomization adherence screen: The studies of left ventricular dysfunction experience (1992) (1)
Clinical trial dropouts: Analysis of demography and reasons (1981) (1)
11-16 Part 2 : Screening and Recruitment (2005) (1)
Natriuretic peptides predict left ventricular remodeling in response to metoprolol CR in patients with congestive heart failure: the RESOLVD phase II neurohumoral substudy (2002) (1)
Abstract Fifteenth Annual Meeting of the Society for Clinical Trials The Westin Galleria Hotel, Houston, Texas May 8–11, 199476P J-shaped compliance distribution: Revised (1994) (1)
CAD-32: Évaluation de Lixisenatide dans le syndrome coronarien aigu (ELIXA : Evaluation of LIXisenatide in Acute Coronary Syndrome) (2016) (1)
Garlic tablets are ineffective in hypercholesterolemia. (1998) (1)
Developing simulated patients for training and evaluating trial staff in adherence counseling (1982) (1)
Ethacrynic Acid Induced Inotropism 1 (1975) (1)
The health behaviors questionnaire for predicting adherence to prescribed regimens: Development and standardization (1982) (1)
Erectile Dysfunction and Incidence of Cardiovascular Disease—Reply (2006) (1)
Neurohumoral variability in left ventricular dysfunction. SOLVD Investigators. Studies of Left Ventricular Dysfunction. (1995) (1)
Lesions and in Human Plasma Association of Angiotensin-Converting Enzyme With Low-Density Lipoprotein in Aortic (2002) (0)
EFFECT OF LOW DOSE PREMARIN AND HALOTESTIN ON LIPOPROTEIN IN TURNER SYNDROME (1984) (0)
The role of ACE inhibitors and angiotensin receptor blockers in the treatment of hypertension and cardiovascular disease (2009) (0)
Competency-based survey method for assessing physician clinical trial knowledge and skills (1984) (0)
Risk Factors for New Coronary Events in Older Hispanic Men and Women (2001) (0)
Defining the role of renin/angiotensin-targeted antihypertensive therapy in decreasing cardiovascular risk: evidence, guideline evolution, and questions to be resolved. (2009) (0)
Abstract 11553: Does the Metabolic Syndrome Cluster Provide Incremental Prognostic Information Over the Individual Components? Post Hoc Analysis of the AIM-HIGH Trial (2013) (0)
Scoping Review of Echocardiographic Parameters Associated with Diagnosis and Prognosis After Resuscitated Sudden Cardiac Arrest. (2023) (0)
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial (2022) (0)
Explorer Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail (2020) (0)
DYSGLYCEMIA, EJECTION FRACTION, AND THE RISK OF HEART FAILURE OR CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES AND A RECENT ACUTE CORONARY SYNDROME (2019) (0)
Abstract 13329: MRI-Assessed Carotid Plaque Inflammation Decreases With Lipid Lowering Therapy (2013) (0)
Surrogate endpoint use in cardiovascular clinical trials (1986) (0)
Treatment to Prevent Heart Attack Trial : Results by Sex Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering (2013) (0)
Abstract 295: Aortic Valve Calcium Scores Are Strong Predictors of Aortic Stenosis in a Population-Based Setting: The AGES-Reykjavik Study (2009) (0)
Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management (2017) (0)
Abstract 13355: Clinical Variables Correlated With MRI-assessed Carotid Plaque Neovasculature in Statin-treated Patients (2013) (0)
ACUTE AND CHRONIC EFFECTS OF hGH ON LIPOPROTEINS IN CHILDREN WITH GROWTH HORMONE DEFICIENCY (1984) (0)
Abstract 5751: Aortic Valve Calcification is Prospectively Associated with Primary Cardiovascular Events Independent of Subclinical Coronary Artery Disease Severity: the Multi-Ethnic Study of Atherosclerosis (MESA) (2008) (0)
Impact of MRFIT and CPPT clinical trial results on clinician's practice (1985) (0)
Lipid-lowering therapy and risk of coronary events. Authors' reply (2003) (0)
Erectile dysfunction and incidence of cardiovascular disease. Authors' reply (2006) (0)
·P-25 Recruitment strategies: Studies of left ventricular dysfunction (SOLVD) (1990) (0)
AFMR Eastern Region Annual Meeting Abstracts (2008) (0)
Smoking, high SBP and cholesterol levels were associated with increased risk of carotid artery stenosis. (1998) (0)
Clinical trials methods and the practice of medicine. (1984) (0)
Additional file 1: of Clinical and demographic correlates of medication and visit adherence in a large randomized controlled trial (2016) (0)
Introduction. The cardiovascular continuum in the 21st century: renin-angiotensin system blockade, the cardiovascular continuum in the 21st century. (2010) (0)
Abstract 1305: Erectile Dysfunction Predicts Cardiovascular Events in High Risk Patients Receiving Telmisartan, Ramipril or Both (2009) (0)
·P-24 Staffing patterns and recruitment strategies in systolic hypertension in the elderly program (SHEP) (1990) (0)
Introduction (1991) (0)
The Systolic Hypertension in the Elderly Program (SHEP): Rationale, Design, Recruitment, and Baseline Data (1989) (0)
Use of Lipid‐Lowering Agents in the Prevention of Cardiovascular Disease (2010) (0)
Comment on: Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the united states? A hypothesis. by Hawkins RG et al (2006) (0)
Diagnostic Yield, Safety, and Outcomes of Head-to-Pelvis Sudden Death CT Imaging in Post Arrest Care: The CT FIRST Cohort Study. (2023) (0)
The cost-effectiveness of Rivaroxaban with or without aspirin in the COMPASS trial. (2022) (0)
Atherosclerosis Assessment Confounders in the Rancho (2007) (0)
Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. Editorial (2007) (0)
D054: Visit (VAd) and Medication Adherence (MAd) in the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT): Effect of age and other factors (1998) (0)
Incident cancers in people with dysglycemia and other cardiovascular risk factors: Cohort study of the ORIGIN trial. (2011) (0)
Success in changing established medication dosing schedules in a clinical trial (1984) (0)
Lipid-Lowering Therapy and Risk of Coronary Events--Reply (2003) (0)
Clinical trial results: Impact on clinician (1984) (0)
in Patients with Type 2 Diabetes and Acute Coronary Syndrome (2015) (0)
P109 The role of a Regional Resource Center in a large multicenter clinical study (1995) (0)
222: Lipoproteins in the Prediction of Coronary Artery Calcium (CAC) as Modified by Age in the Multi-Ethnic Study of Atherosclerosis (MESA) (2008) (0)
New findings from completed studies and future directions — systolic hypertension in the elderly trial (shep) (1995) (0)
Survey methods in clinical trials: The bias introduced by incomplete follow-up (1985) (0)
Reply to the letter regarding the article ‘Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial’ (2022) (0)
Chapter 13. Use of Lipid Lowering Agents in the Prevention of Cardiovascular Disease (2007) (0)
Prerandomization adherence aids for clinical trials (1986) (0)
Author Response to Lipid‐Lowering in African Americans in ALLHAT—Optimism Bias? (2013) (0)
·P-23 Screening and recruitment for the systolic hypertension in the elderly program (SHEP) (1990) (0)
Total Events and Net Clinical Benefit of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial (2023) (0)
ASSOCIATION BETWEEN LOW BASELINE TESTOSTERONE LEVELS AND ADVERSE CLINICAL OUTCOMES IN MEN WITH ESTABLISHED CARDIOVASCULAR DISEASE IN THE ATHEROTHROMBOSIS INTERVENTION IN METABOLIC SYNDROME WITH LOW HDL AND HIGH TRIGLYCERIDES AND IMPACT ON GLOBAL HEALTH OUTCOMES TRIAL (2019) (0)
Design issues for studies based on ultrasonographic measurement of the carotid artery intimal-medial thickness (1992) (0)
1421-P: The Impact of Blood Pressure on Risk of Death Is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event (2020) (0)
Angiotensin Antagonism Effect of Long-Term Therapy With Ramipril in High-Risk Women (2016) (0)
Effect ofLovastatin on EarlyCarotid Atherosclerosis andCardiovascular Events (2011) (0)
Abstract 3680: Glucose Levels Predict Incident Cardiovascular Events In A Large International Multiethnic Cohort (2007) (0)
At what level should LDL-cholesterol be reduced for secondary prevention? Rationale and design of the NIH Post-CABG clinical trial (1994) (0)
Ramipril Global Endpoint Trial / Telmisartan Randomized AssessmeNt Study in ACE withTelmisartan , Ramipril , or Both : The ONgoing Telmisartan Alone and in combination Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving (2010) (0)
Reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jeffrey Lynn Probstfield?

Jeffrey Lynn Probstfield is affiliated with the following schools: